Ascendis Pharma Introduces Vision 2030 - Seite 2
Vision 2030: Ascendis Pharma’s 2025–2030 Strategic Roadmap
Achieve blockbuster status for multiple products and expand our engine for future innovation.
- Be the Leading Endocrinology Rare Disease Company
- Achieve blockbuster status (>$1B) for TransCon PTH, TransCon hGH, and TransCon CNP through worldwide commercialization
- Be the leader in growth disorders and hypoparathyroidism, pursuing clinical conditions, innovative life cycle management, and complementary patient offerings
- Expand pipeline with Endocrinology Rare Disease blockbuster product opportunities
- Achieve blockbuster status (>$1B) for TransCon PTH, TransCon hGH, and TransCon CNP through worldwide commercialization
- Create Value in Additional Therapeutic Areas through Innovative Business Models
- Obtain accelerated approval in oncology with registrational trials ongoing
- Pursue TransCon product opportunities in >$5B indications
- Maximize value creation of these product opportunities through collaboration with therapeutic area market leaders
- Differentiate with Ascendis Fundamentals
- Outperform industry drug development benchmarks with Ascendis’ product innovation algorithm
- Remain independent as a profitable biopharma through lean and flexible ways of working
- Let our values Patients, Science, Passion drive our decisions to success
Presentation at J.P. Morgan Healthcare Conference on Monday, January 8th
A live webcast of the event will be available via the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. The presentation will begin at 12:00 p.m. Eastern Time / 9:00 am Pacific Time. A webcast replay will be available for 30 days.
The Company’s slides from the J.P. Morgan presentation will be available on the same Investor Relations website at https://investors.ascendispharma.com.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Germany and the United States. Please visit ascendispharma.com to learn more.